ALMS

3.9608.55%
JB

James Bruce Tananbaum

Independent Director

Dr. James Bruce Tananbaum, MBA, MD, also known as Jim, is Founder of Foresite Capital Management, LLC and also serves as Chief Executive Officer. He joined the firm in 2011. At Foresite Capital Management, LLC, he also served as Chief Executive Officer, Founding Partner and Managing Director from 2011. He is Co-Founder of Prospect Venture Partners and also serves as Affliate Partner. He serves as Director of Patient Care, Inc., Director of Shaklee Global Group,Inc. since 2013, Director of California Life Sciences Association, Director of Sequenta, Inc., Director of Genomics Limited and Director of Mindstrong, Inc. He serves as Non-Executive Director of Evonetix Ltd. He served as Director of Element Biosciences, Inc. since September 2017 until August 2026. He serves as Director of Latigo Biotherapeutics, Inc. since July 2024. He serves as Chairman of Interline Therapeutics, Inc. He serves as Chief Executive Officer of Pardes Biosciences, Inc. He serves as President, Chief Executive Officer and Director of Foresite Life Sciences Corp. since January 2021. He serves as Independent Director of Alumis Inc. since May 2021. He serves as Founder & CEO of Foresite Capital of Spear Bio, Inc. since March 2026. He serves as Director of Foresight Diagnostics, Inc. since 2025. He is Co-Founder of Foresite Labs, LLC. He serves as Board Member of identifeye HEALTH Inc. since May 2026. He serves as Board Observer of Xaira Therapeutics, Inc. He serves as Director of Inscripta, Inc. since February 2025. He served as Board Observer of identifeye HEALTH Inc. from July 2025 to May 2026 and as Board Member until July 2025. He served as Independent Director at Eikon Therapeutics, Inc. from July 2025 to January 24, 2026 and also served as Director. He served as Independent Director of Quantum-Si incorporated from June 10, 2021 to May 10, 2022. He served as Independent Director at Kinnate Biopharma Inc. from June 2020 to April 3, 2024 and from March 2018 to December 2019. He served as Director of Gemini Therapeutics, Inc. from June 2020. He served as President, Chief Executive Officer and Director of FS Development Corp. II from August 2020. He served as President, Chief Executive Officer and Director of FS Development Corp. from June 2020. He served as Director at Fulcrum Therapeutics, Inc., where he was employed until April 03, 2019. He served as Director at Tarsa Therapeutics, Inc., where he was employed until 2018. He served as Director at Vitae Pharmaceuticals, Inc., where he was employed until September 01, 2013. He served as Director at Infinity Pharmaceuticals, Inc., where he was employed from September 2006 to May 15, 2012. He served as Director at Jazz Pharmaceuticals plc, where he was employed from 2003 to May 24, 2011. He served as Director at Novavax, Inc., where he was employed from April 26, 2006 to October 2009. He served as Director at Critical Therapeutics, Inc., where he was employed from July 05, 2005 to June 22, 2007. He served as Director at Vanda Pharmaceuticals Inc., where he was employed from 2004 to June 2007. He served as Director of Amira Pharmaceuticals, Inc., which he joined on November 28, 2005. He served as Director of Intensiva HealthCare Corporation, which he joined in December 1994. He is Co-Founder of Pathwork Diagnostics, Inc. and also served as Director, joining in 2002. He also served as Chief Executive Officer and Director at Pardes Biosciences, Inc. and as Director from January 2021. He served as Senior Product Manager of Merck & Co., Inc. He served as Chief Executive Officer, President and Director of Innoviva, Inc. He served as Director of NovaMed Inc. He is Founder of GelTex Pharmaceuticals, Inc. and also served as Executive Officer. He served as Director of ROXRO PHARMA, Inc. He is Co-Founder of Cogentus Pharmaceuticals, Inc. He served as Partner of Sierra Ventures Management, LLC. He served as Director of LookSmart Group, Inc. He served as Director of Aimmune Therapeutics, Inc. He is Co-Founder of Theravance and also served as its founding Chief Executive Officer. He is Co-Founder of Prospect Ventures. His career in healthcare investment spans several years. He has been driven by a conviction that breakthroughs occur when disciplines converge, with enduring passions in mathematics, computer science, biology and medicine. He believed that computation would fundamentally reshape the discovery, development and delivery of healthcare. He established the healthcare investing practice at Sierra Ventures. He has an M.B.A. from Harvard University in 1991, an M.D. from Harvard University in 1989, an M.S. from Massachusetts Institute of Technology and a B.S. in Computer Science, Applied Mathematics & Electrical Engineering from Yale University in 1985.

Positions